Indications

Clostridium Difficile Colitis (see Clostridium Difficile)

General Comments

• FDA-Approved for This Indication in 2022

Clinical Efficacy

• Phase 3 PUNCH CD3 Trial of RB2660 (XXXXX) [MEDLINE]
  • XXXX

---

Pharmacology

XXXXX

• xxx

Metabolism

• xxx

---

Administration

XXXXX

• xxx

Dose Adjustment

• Hepatic: xxx
• Renal: xxx

Use in Pregnancy (see Pregnancy)

• xxx

Use During Breast Feeding

• xxx

---

Adverse Effects

Other Adverse Effects

• xxx
• xxx
• xxx
• xxx

---

References

• xxx